Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements.

Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, Meeker AK, Netto G, De Marzo AM, Nelson WG, Yegnasubramanian S.

Nat Genet. 2010 Aug;42(8):668-75. doi: 10.1038/ng.613. Epub 2010 Jul 4.

2.

Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.

Kolar Z, Burdova A, Jamaspishvili T, Bouchal J, Kucerova R, Bienova M, Kral M, Student V.

Neoplasma. 2014;61(1):9-16.

PMID:
24195515
3.

Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.

Todorova K, Metodiev MV, Metodieva G, Mincheff M, Fernández N, Hayrabedyan S.

Horm Cancer. 2017 Feb;8(1):28-48. doi: 10.1007/s12672-016-0279-9. Epub 2017 Jan 3.

PMID:
28050800
4.

TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.

Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI, Peltola M, Smit F, Verhaegh G, Schalken J, Nees M, Kallioniemi O.

Cancer Res. 2006 Nov 1;66(21):10242-6.

5.

Transcription-induced DNA double strand breaks: both oncogenic force and potential therapeutic target?

Haffner MC, De Marzo AM, Meeker AK, Nelson WG, Yegnasubramanian S.

Clin Cancer Res. 2011 Jun 15;17(12):3858-64. doi: 10.1158/1078-0432.CCR-10-2044. Epub 2011 Mar 8.

6.

[The progress of TMPRSS2-ETS gene fusions and their mechanism in prostate cancer].

Guo XQ, Gui YT, Cai ZM.

Yi Chuan. 2011 Feb;33(2):117-22. Review. Chinese.

PMID:
21377967
7.

Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.

Kolar Z, Burdova A, Jamaspishvili T, Bouchal J, Kucerova R, Bienova M, Kral M, Student V.

Neoplasma. 2013 Sep 20. doi: 10.4149/neo_2014_004. [Epub ahead of print]

PMID:
24050545
8.

NKX3.1 Suppresses TMPRSS2-ERG Gene Rearrangement and Mediates Repair of Androgen Receptor-Induced DNA Damage.

Bowen C, Zheng T, Gelmann EP.

Cancer Res. 2015 Jul 1;75(13):2686-98. doi: 10.1158/0008-5472.CAN-14-3387. Epub 2015 May 14.

9.

Emerging biological observations in prostate cancer.

Shah S, Small E.

Expert Rev Anticancer Ther. 2010 Jan;10(1):89-101. doi: 10.1586/era.09.161. Review.

PMID:
20014889
10.

Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.

Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM, Shah RB.

Mod Pathol. 2007 May;20(5):538-44. Epub 2007 Mar 2.

11.

Induced chromosomal proximity and gene fusions in prostate cancer.

Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, Palanisamy N, Chinnaiyan AM.

Science. 2009 Nov 27;326(5957):1230. doi: 10.1126/science.1178124. Epub 2009 Oct 29.

12.

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.

Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, Cheng H, Laxman B, Vellaichamy A, Shankar S, Li Y, Dhanasekaran SM, Morey R, Barrette T, Lonigro RJ, Tomlins SA, Varambally S, Qin ZS, Chinnaiyan AM.

Cancer Cell. 2010 May 18;17(5):443-54. doi: 10.1016/j.ccr.2010.03.018.

13.

Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells.

Li Y, Kong D, Wang Z, Ahmad A, Bao B, Padhye S, Sarkar FH.

Cancer Prev Res (Phila). 2011 Sep;4(9):1495-506. doi: 10.1158/1940-6207.CAPR-11-0077. Epub 2011 Jun 16.

14.

Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.

Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM.

Nature. 2007 Aug 2;448(7153):595-9.

15.

Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer.

Weier C, Haffner MC, Mosbruger T, Esopi DM, Hicks J, Zheng Q, Fedor H, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S.

J Pathol. 2013 Jun;230(2):174-83. doi: 10.1002/path.4186.

16.

A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis.

Lapointe J, Kim YH, Miller MA, Li C, Kaygusuz G, van de Rijn M, Huntsman DG, Brooks JD, Pollack JR.

Mod Pathol. 2007 Apr;20(4):467-73. Epub 2007 Mar 2.

17.

Androgen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells.

Farooqi AA, Hou MF, Chen CC, Wang CL, Chang HW.

Cancer Cell Int. 2014 Apr 17;14:34. doi: 10.1186/1475-2867-14-34. eCollection 2014. Review.

18.

Recurrent rearrangements in prostate cancer: causes and therapeutic potential.

White NM, Feng FY, Maher CA.

Curr Drug Targets. 2013 Apr;14(4):450-9. Review.

19.

Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study.

Sun QP, Li LY, Chen Z, Pang J, Yang WJ, Zhou XF, Qiu JG, Su ZL, He D, Gao X.

J Mol Diagn. 2010 Sep;12(5):718-24. doi: 10.2353/jmoldx.2010.100002. Epub 2010 Jul 8.

20.

Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers.

Liu W, Ewing CM, Chang BL, Li T, Sun J, Turner AR, Dimitrov L, Zhu Y, Sun J, Kim JW, Zheng SL, Isaacs WB, Xu J.

Genes Chromosomes Cancer. 2007 Nov;46(11):972-80.

PMID:
17654723

Supplemental Content

Support Center